Atipamezole Market Forecasted for Accelerated Growth in Pharmaceuticals Sector 2023

By , in PR PR World on .

Portland, OR — 12/22/2017 — Atipamezole is a synthetic alpha 2 adrenergic receptor antagonist drug, which reverses the effects of sedative and analgesic drugs such as medetomidine, xylazine, amitraz, and detomidine among others, in animals. In addition, it is used to treat amitraz and imidazoline decongestants toxicity in animals.

Get sample copy @ https://www.alliedmarketresearch.com/request-toc-and-sample/3352

Reduction in sedative time of animals shortens the in-clinic stay, saves the time of the staff, reduces hospitalization costs, and reduces revisits of the animal owner. Furthermore, the rising pet ownership and increasing healthcare expenditure on animals are anticipated to fuel the market growth. However, adverse effects of atipamezole and stringent government regulations associated with the safety and efficacy of atipamezole is anticipated to hinder the market growth. For instance, atipamezole is not approved for use in cats in the U.S. Ongoing R&D activities on atipamezole is anticipated to provide opportunities for the market growth.

The market is segmented on the basis of application, route of administration, and geography. Based on application, the market is divided into anti-sedative and others (anti-analgesic and amitraz toxicity). By route of administration, the market is segmented into intravenous, intramuscular, and others (subcutaneous and intraperitoneal). Geographically, the market has been analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Browse full report @ https://www.alliedmarketresearch.com/atipamezole-market

The following two tabs change content below.
Sarah Thompson

Sarah Thompson

Sarah is a financial reporter, focusing on technology, national security, and policing. Before joining Daily Telescope she worked as a staff writer at Fast Company and spent two years as a foreign correspondent in Turkey. Her work has been published in Al Jazeera America, The Nation, Vice News, Motherboard, and many other outlets.
%d bloggers like this: